NETRAMARK TO HOST SHAREHOLDER CONFERENCE CALL TO DISCUSS BUSINESS MOMENTUM
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), an AI company specializing in clinical trials analytics, has announced a shareholder conference call scheduled for Tuesday, April 15, 2025, from 4:00-4:30pm EST. CEO George Achilleos will lead the discussion on recent developments and growth strategies.
Key highlights include a strategic partnership with Worldwide Clinical Trials, which is integrating NetraAI into various clinical trials, particularly in neuroscience and oncology. The company will discuss its regulatory alignment strategy, focusing on how its explainable AI capabilities support clinical trials and FDA submissions.
The call will also showcase NetraAI's technological differentiation, highlighting its ability to identify subpopulations in small datasets and reduce overfitting. Additionally, NetraMark has extended its agreement with 1502656 B.C for public relations services, with additional compensation of $200,000 CDN for a six-month term.
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), un'azienda di intelligenza artificiale specializzata nell'analisi di studi clinici, ha annunciato una conferenza telefonica per gli azionisti programmata per martedì 15 aprile 2025, dalle 16:00 alle 16:30 EST. Il CEO George Achilleos guiderà la discussione sugli sviluppi recenti e le strategie di crescita.
I punti salienti includono una partnership strategica con Worldwide Clinical Trials, che sta integrando NetraAI in vari studi clinici, in particolare in neuroscienze e oncologia. L'azienda discuterà la sua strategia di allineamento normativo, concentrandosi su come le sue capacità di intelligenza artificiale spiegabile supportino gli studi clinici e le presentazioni alla FDA.
La chiamata metterà in evidenza anche la differenziazione tecnologica di NetraAI, sottolineando la sua capacità di identificare sottogruppi in piccoli set di dati e ridurre il sovradattamento. Inoltre, NetraMark ha esteso il suo accordo con 1502656 B.C per servizi di pubbliche relazioni, con un compenso aggiuntivo di 200.000 dollari CDN per un periodo di sei mesi.
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), una empresa de inteligencia artificial especializada en análisis de ensayos clínicos, ha anunciado una conferencia telefónica para accionistas programada para el martes 15 de abril de 2025, de 4:00 a 4:30 p.m. EST. El CEO George Achilleos liderará la discusión sobre los desarrollos recientes y las estrategias de crecimiento.
Los aspectos destacados incluyen una asociación estratégica con Worldwide Clinical Trials, que está integrando NetraAI en varios ensayos clínicos, particularmente en neurología y oncología. La empresa discutirá su estrategia de alineación regulatoria, centrándose en cómo sus capacidades de inteligencia artificial explicable apoyan los ensayos clínicos y las presentaciones a la FDA.
La llamada también destacará la diferenciación tecnológica de NetraAI, subrayando su capacidad para identificar subpoblaciones en conjuntos de datos pequeños y reducir el sobreajuste. Además, NetraMark ha ampliado su acuerdo con 1502656 B.C para servicios de relaciones públicas, con una compensación adicional de 200,000 dólares CDN por un período de seis meses.
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), 임상 시험 분석을 전문으로 하는 인공지능 회사가 2025년 4월 15일 화요일 오후 4시부터 4시 30분(EST)까지 주주 회의 전화를 개최한다고 발표했습니다. CEO 조지 아킬레오스가 최근의 발전 및 성장 전략에 대한 토론을 이끌 것입니다.
주요 하이라이트로는 Worldwide Clinical Trials와의 전략적 파트너십이 포함되어 있으며, 이는 NetraAI를 신경과학 및 종양학 분야의 다양한 임상 시험에 통합하고 있습니다. 이 회사는 임상 시험 및 FDA 제출을 지원하는 설명 가능한 AI 기능에 중점을 두고 규제 정렬 전략을 논의할 것입니다.
이번 통화에서는 NetraAI의 기술적 차별화도 강조될 것이며, 작은 데이터 세트에서 하위 집단을 식별하고 과적합을 줄이는 능력을 강조합니다. 또한, NetraMark는 1502656 B.C와의 공공 관계 서비스 계약을 연장했으며, 6개월 동안 200,000 캐나다 달러의 추가 보상을 받습니다.
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), une entreprise d'intelligence artificielle spécialisée dans l'analyse des essais cliniques, a annoncé une conférence téléphonique pour les actionnaires prévue pour le mardi 15 avril 2025, de 16h00 à 16h30 EST. Le PDG George Achilleos dirigera la discussion sur les développements récents et les stratégies de croissance.
Les points clés incluent un partenariat stratégique avec Worldwide Clinical Trials, qui intègre NetraAI dans divers essais cliniques, en particulier en neurosciences et en oncologie. L'entreprise discutera de sa stratégie d'alignement réglementaire, en se concentrant sur la manière dont ses capacités d'IA explicable soutiennent les essais cliniques et les soumissions à la FDA.
La conférence mettra également en avant la différenciation technologique de NetraAI, soulignant sa capacité à identifier des sous-populations dans de petits ensembles de données et à réduire le surajustement. De plus, NetraMark a prolongé son accord avec 1502656 B.C pour des services de relations publiques, avec une compensation supplémentaire de 200 000 CAD pour une période de six mois.
NetraMark Holdings (CSE: AIAI) (OTCQB: AINMF), ein Unternehmen für künstliche Intelligenz, das sich auf die Analyse klinischer Studien spezialisiert hat, hat eine Telefonkonferenz für Aktionäre angekündigt, die für Dienstag, den 15. April 2025, von 16:00 bis 16:30 Uhr EST geplant ist. CEO George Achilleos wird die Diskussion über die aktuellen Entwicklungen und Wachstumsstrategien leiten.
Wichtige Highlights sind eine strategische Partnerschaft mit Worldwide Clinical Trials, die NetraAI in verschiedene klinische Studien, insbesondere in der Neurowissenschaft und Onkologie, integriert. Das Unternehmen wird seine Strategie zur regulatorischen Ausrichtung diskutieren, wobei der Fokus darauf liegt, wie seine erklärbare KI-Fähigkeiten klinische Studien und FDA-Einreichungen unterstützen.
Die Telefonkonferenz wird auch die technologische Differenzierung von NetraAI hervorheben, insbesondere die Fähigkeit, Subpopulationen in kleinen Datensätzen zu identifizieren und Überanpassung zu reduzieren. Darüber hinaus hat NetraMark seine Vereinbarung mit 1502656 B.C für Öffentlichkeitsarbeit verlängert, mit einer zusätzlichen Vergütung von 200.000 CAD für einen Zeitraum von sechs Monaten.
- None.
- None.
The call will be hosted by NetraMark CEO George Achilleos and will focus on the Company's expanding commercial footprint, its approach to its interactions with regulatory submissions, and the operational strategy that continues to drive innovation in patient-centric clinical trial design.
Conference Call In Details:
Tuesday, April 15 • 4:00 – 4:30pm
Time zone:
Video call link: https://join.freeconferencecall.com/netramark0415
Or dial: (CA) 1-605-313-5544 Access Code: 8003978#
Please note: A recording of the call will be made available at the NetraMark.com website.
Conference Call Highlights Will Include:
- Strategic Partnerships Driving Growth
NetraMark has recently established a key global partnership with a prominent contract research organization (CRO) Worldwide Clinical Trials, which is now integrating NetraAI into a broad range of clinical trials. This collaboration is expected to significantly increase exposure and adoption of NetraMark's technology across therapeutic areas, particularly in neuroscience and oncology.
- Regulatory Pathway
NetraMark will provide insight into its strategy for regulatory alignment, including how its explainable AI capabilities are designed to support clinical trials and improve the quality of submissions to regulatory bodies, such as the FDA.
- Technology Differentiation and Roadmap
Attendees will hear how NetraAI stands apart from conventional AI by focusing on explainable and actionable insights, using novel algorithms to identify subpopulations in small datasets and reduce overfitting. The Company will also provide a glimpse into upcoming enhancements and applications of its technology.
"Our Company is in an exciting phase of growth and transformation," said George Achilleos, CEO of NetraMark. "We've taken important steps to scale our technology. This call will be an opportunity to share our vision, highlight our progress, and connect directly with our shareholders."
Marketing, Public and Investor Relations
NetraMark also announces that it has extended the term of its original agreement ("BC Agreement") with 1502656 B.C LTD. ("BC Ltd.) to provide public relations services in an effort to increase public awareness of the Company. Certain services provided by BC Ltd. include "investor relations activities" under the policies of the Canadian Securities Exchange. The term of the BC Agreement is extended six (6) months and amended to provide for additional compensation paid during the term to BC Ltd. of
As of the date hereof, to the Company's knowledge, BC Ltd. (including its directors and officers) do not own any securities of the Company. BC Ltd. is located at 3849 154th Street
About NetraAI
In contrast with other AI-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) that have the potential to increase the chances of a clinical trial success. Other AI methods lack these focus mechanisms and assign every patient to a class, even when this leads to "overfitting" which drowns out critical information that could have been used to improve a trial's chance of success.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the expectation to significantly increase exposure and adoption of NetraMark's technology across therapeutic areas through its collaboration with Worldwide Clinical Trials; the highlights to be discussed at the upcoming conference call; steps taken by the Company to scale its technology; and the terms and objectives of the BC Agreement, which are based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.
When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management's Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/netramark-to-host-shareholder-conference-call-to-discuss-business-momentum-302426006.html
SOURCE NetraMark Holdings Inc.
FAQ
When is NetraMark's (AINMF) shareholder conference call scheduled for April 2025?
What is the strategic partnership announced between NetraMark (AINMF) and Worldwide Clinical Trials?
How does NetraMark's (AINMF) AI technology differentiate itself in clinical trials?
What is the value of NetraMark's (AINMF) extended PR services agreement with BC ?
How can investors access NetraMark's (AINMF) April 2025 conference call?
